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Background: Understanding how patients generate preferences for administration route alternatives may improve
health-care delivery and clinical outcomes. Recently, novel biological therapies with subcutaneous (SC) and
intravenous (IV) administration routes have been approved for severe uncontrolled asthma. The aim of our study
was to assess the preferred route of biologic therapy administration and related beliefs among patients with severe
uncontrolled asthma.
Methods: We conducted a cross-sectional observational survey study. Patients answered an anonymous, self-
administered questionnaire after an outpatient visit in pulmonary disease clinics located throughout Italy.
Socio-demographic and clinical information together with the 12-Item Short Form Survey (SF-12), Work Pro-
ductivity Impairment Scale and the medical resources utilization module of the Health & Work Survey were
collected. Patients beliefs and preference towards SC and IV administration were investigated by means of an ad
hoc 13 item questionnaire.
Results: the main findings: 150 patients fulfilled the inclusion criteria and completed the questionnaire (47.3%
males). Preference for IV and SC administration was 18.7% and 81.3%, respectively. Compared with patients
preferring SC formulation, patients that favored IV were older (p ¼ 0.04), less likely to escalate corticosteroid dose
(p ¼ 0.03) and had emergency room (ER) access (p ¼ 0.009) during asthma exacerbations. Patients felt that SC
was more convenient than IV, but this belief was not associated with higher likelihood of preferring SC admin-
istration. IV formulations were more likely associated with quicker and more effective drug action (p ¼ 0.0001),
procedural safety and medical oversight (p ¼ 0.0002) and social support (p ¼ 0.007). Predictors of IV preference
were represented by the association of worse asthma control and increased use of ER services, and by beliefs
toward formulation effectiveness/efficiency in reducing symptoms (p ¼ 0.04 and p < 0.0001, respectively). The
model achieved excellent discrimination of administration route preference (area under the curve ¼ 0.87).
Conclusions: Preference is guided by partially misleading beliefs, which may generate wrong expectations that in
turn can affect treatment satisfaction and adherence. Convenience and efficacy beliefs for drugs with different
routes of administration always should be discussed with patients to achieve informed shared-decision making.
Trial registration: Not applicable.cal and Clinical Sciences (DIBIC), University of Milan Section of Respiratory Diseases, L. Sacco Hospital, ASST
ilano, Italy.
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Patient involvement in Shared Decision Making (SDM) is gaining
increasing emphasis in health care policies.1,2 Within the collaborative
process with their health care professionals, patients are provided with
detailed information about treatment and medical options, and their
preferences are discussed in a supportive communication in order to
obtain a shared decision.3 Besides preferences, patients’ beliefs and at-
titudes towards medication should also be elicited as they may be asso-
ciated with treatment adherence.4–6 Hence, shared decision making
should be particularly encouraged for long-term management of chronic
conditions7 as it has been shown to have a relevant role in fostering
medication adherence.8
Patients’ preferences acquire greater importance when treatment
choices are equally effective and management options may be valued, yet
help patients develop more accurate expectations of treatment
outcomes.9
Particularly, patients’ preference for injection routes of administra-
tion (i.e. intravenous, subcutaneous, intramuscular) achieves a promi-
nent role as it accounts for different potential advantages or drawbacks
considering dose, frequencies and duration of administration, associated
pain or discomfort, treatment speed of action, safety profile, and home or
hospital setting for drug delivery.10
Once equal safety and efficacy parameters have been established,
considering patients’ preferences for route of administration should be an
essential principle for clinicians to consider in order to better ensure
patient compliance.10
Head-to-head studies comparing intravenous (IV) and subcutaneous
(SC) routes of administration suggest the latter being the preferred
method of drug administration by patients because it is associated with
home setting treatment, saved time, overall reduced discomfort and
fewer complications related to poor vein access.11 However, these studies
focused on specific drugs whose available routes of administration may
substantially vary, since SC formulation allows the possibility of
home-based self-injection (e.g. anti-TNF agents, immunoglobulin, insu-
lin) as well as a significant reduction of infusion duration (e.g. trastu-
zumab, rituximab). Conversely, IV route may be preferred, as hospital
care setting appears to be associated with a safer treatment and the
reassuring effect of physician presence.12,13
Among biologic therapies traditionally delivered by IV formulation,
SC route of administration has increasingly been licensed, thus offering
to patients a comparable alternative.14 So far, patient preference studies
comparing IV and SC for biologic therapies have mainly focused on in-
flammatory bowel disease,15–17 breast cancer,18 rheumatoid and psori-
atic arthritis.12,13,19
For the treatment of severe uncontrolled asthma, different mono-
clonal antibodies (mAbs) have proven effective.20 Recently, mABs
directed against interleukin (IL)-5 (mepolizumab and reslizumab) and its
receptor showed efficacy for patients with uncontrolled severe asthma in
whom eosinophils play a dominant pathobiologic role,21 and they have
been approved as add-on therapies by the U.S. Food and Drug Admin-
istration and the European Medicines Agency. These drugs are available
for IV or SC formulation and may vary in reference to dosage and fre-
quency of administration.22,23 Although in a 10-patient study,
weight-adjusted IV reslizumab showed better clinical outcomes as
compared to fixed-dose SC mepolizumab,24 head-to-head studies
comparing IV or SC administration for different mAbs are limited and
superiority is difficult to determine.17,25 Additionally, no studies so far
have investigated preferences for IL-5 mABs IV or SC formulation among
patients with uncontrolled severe asthma. Understanding how patients
generate preferences for administration route alternatives may improve
health-care delivery and clinical outcomes, thus providing physicians
with better knowledge when approaching SDM.
The aim of our study was to assess the preferred route of biologic




We conducted a cross-sectional observational survey study. Patients
answered an anonymous, self-administered questionnaire after an
outpatient visit in pulmonary disease clinics located throughout Italy. We
enrolled adult patients younger than 75 years of age, without chronic
respiratory tract comorbidities (i.e. chronic obstructive pulmonary dis-
ease, pulmonary fibrosis, emphysema, and cancer), and we restricted
study inclusion to patients with poorly controlled asthma as determined
by Asthma Control Questionnaire 6-item score (ACQ-6) 1.526–28 despite
use of medium/high dose of inhaled corticosteroids/beta-adrenergic ag-
onists combinations in the previous 12 months. Patients receiving a bio-
logic therapy for severe asthma were not excluded from the study. No
personal identifiers can be deducted from the answers to the question-
naire. After filling in the questionnaire, patients put the survey packet into
an anonymous envelope and returned it to a study assistant so that pa-
tients' answers could not be matched to subjects’ identity. According to
the Italian regulation,29 cross-sectional survey research based on anony-
mous questionnaires do not require ethical committee approval.
Measures
The questionnaire packet included a brief screener questionnaire
(BSQ) tapping socio-demographic (i.e. age, geographic region, gender)
and clinical information (diagnosis of asthma, presence of any other lung
diseases, assessment of asthma control, concurrent asthma related
treatments and routes of administration, remedies to exacerbations
occurred in the previous 12 months). Responses to the BSQ were used to
determine study eligibility. Furthermore, we collected information con-
cerning patients' history of exacerbations according to expert consensus
definition30; in order to facilitate patients’ recall of exacerbation episodes
occurred in the previous 12 months we provided the event definition as a
primer: “Exacerbations - commonly referred to as asthma attacks or acute
asthma - are episodes of progressive increase in shortness of breath, cough,
wheezing, chest tightness, or a combination of these symptoms which occur
despite the regular assumption of usual therapy. When an exacerbation occurs,
it is required to assume a systemic corticosteroid treatment or at least a
doubling of existing dose for maintenance oral corticosteroid and/or a hos-
pitalization and/or an emergency department visit”. We asked to report the
frequency of episodes occurred in the past 12 months and recourse to
hospitalization, emergency room visits, corticosteroid therapy initiation
or dose escalation. We also collected employment status according to the
International Labour Office definition and past/current exposure to po-
tential occupational or environmental risk factors for asthma.
Additionally, the questionnaire packet included the 12-Item Short
Form Survey (SF-12), Work Productivity Impairment Scale, and the
medical resources utilization module of the Health & Work Survey31–33
(Additional file 1).
Patients beliefs on IV and SC route of administration of biologic therapy
Since no valid scale tapping patients’ beliefs toward IV/SC adminis-
tration route exists, we were forced to devise an ad hoc scale for the study.
Seventeen items (i.e. beliefs) were generated by literature review and
expert opinion (Additional file 2).10,13,34 Before answering the beliefs
scale, patients were primed with statements describing the indication for
biologic therapy and the procedure involved for both IV and SC admin-
istration modality (Additional file 3). Patients were asked to rate how
much they believed that either one of the two administration modalities
was characterized by the 17 attributes generated, which were pertaining
to four factors: a) procedural safety and medical oversight (e.g. “It allows
a closer medical oversight during drug administration”); b) efficacy and
speed of action (e.g. “It allows greater speed of action of the drug (the drug
takes effect earlier”); c) social support (e.g. “It allows to have closer
Table 1
Factor analysis and related reliability concerning beliefs towards IV and SC route of administration.





Allows greater safety during administration 0.184 0.521 0.549 0.078
Allows a closer medical oversight during drug administration 0.101 0.134 0.864 0.199
Allows to receive treatment in a protected and safe setting 0.039 0.123 0.870 0.172
Allows greater drug efficacy 0.118 0.492 0.333 0.521
Allows greater speed of action of the drug (the drug takes effect earlier) 0.005 0.264 0.265 0.742
Allows less frequent drug administration 0.031 0.046 0.025 0.828
Allows greater convenience 0.736 0.038 0.025 0.238
Allows less time spent managing asthma 0.755 0.127 0.036 0.018
Allows to have more time for non disease-related daily activities 0.779 0.144 0.119 0.205
Allows to have less hassles about asthma 0.703 0.172 0.344 0.069
Allows a better interactions with the medical staff 0.023 0.775 0.004 0.322
Allows to interact with other patients and share worries and concerns 0.302 0.664 0.100 0.041
Allows to have closer relationships with medical staff 0.211 0.797 0.263 0.070
Cronbach Coefficient Alpha 0.751 0.689 0.781 0.689
P. Santus et al. World Allergy Organization Journal 12 (2019) 100030relationships with medical staff”); d) convenience of administration (e.g. “It
allows less time spent managing asthma”). Ratings occurred through a bi-
polar scale of evaluation (2, strong belief that attributes specifically
characterize SC; 1 mild belief that attributes specifically characterize
SC; 0 ¼ attributes characterize both modalities equally; 1 ¼ mild belief
that attributes specifically characterize IV; 2 ¼ strong belief that attri-
butes specifically characterize IV). The content of the 13 selected items
based on factor analysis is reported in Table 1.
Additionally, patients were asked to choose either IV or SC route of
administration in case their attending physician would have prescribed
them a biologic therapy (Additional file 3).
Statistical analysis
Means and standard deviations or absolute and relative frequencies
were respectively computed for continuous or categorical variables.
The association between patients’ preference for IV or SC route of
administration and socio-demographic and clinical characteristics has
been evaluated with t-test or χ2 test for continuous or categorical vari-
ables respectively. We adopted a stepwise logistic regression (entry cri-
terion: p < 0.030; stay criterion: p < 0.010) to assess independent
correlates of IV or SC route of administration. We adjusted the multi-
variable model for socio-demographic (age, sex, geographic area,
employment status, high-risk occupation) and clinical characteristics
(disease duration, ACQ-6 score, complexity of treatment regimen, exac-
erbation remedies, current and previous medication for asthma, medical
resources utilization, mental and physical SF-12 composite scores, sleep
quality, BMI, work productivity and activity impairment, suffering fromTable 2
Hypothetical clinical scenarios illustrating adjusted probability of preferring the IV r













a Numbers represent increase (1,2) or reduction (1) of standard deviations from th
ER services in case of exacerbations ¼ 0.96, sd ¼ 0.80; speed of action of drug (belief
sample average (Regimen Complexity: 2.12; BMI: 24).
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allergy, experience with biologic therapy for asthma). P < 0.05 was
considered statistically significant.
In order to help facilitate the interpretation of the multivariable
analysis and the impact of the cross-interaction observed, we calculated
the predicted probability of preferring the IV administration route for ten
hypothetical patients with different demographic characteristics, clinical
factors and beliefs, based on the estimated parameters of the logistic
regression (Table 2). Factor analysis and related reliability concerning
beliefs towards IV and SC route of administration are shown in Table 1.
Analyses were conducted with SAS 9.4 ™.
Results
One hundred and fifty patients fulfilled the inclusion criteria and
completed the questionnaire. Table 3 shows socio-demographic and
clinical characteristics of the whole sample and the subset of patients
who expressed preference for IV (18.7%) or SC (81.3%) route of
administration.
In total, half of the sample (50.7%) was currently taking corticoste-
roid; SC biologic therapy was the current therapy for 32% of patients
(among these, 31 subjects (64.8%) were treated with omalizumab, 17
subjects (35.4%) with mepolizumab), whereas 4% had past experience
with biologic drugs. Disease duration was 25 years on average (sd ¼
12.4), which represented about half their lives (48.8 y; sd ¼ 12.1). In the
previous 12 months, subjects had access almost twice to the emergency
room (ER) and received 4.55 outpatient visits due to asthma-related
complications; remedies to last exacerbation mainly consisted in corti-
costeroid dose escalation (1.76 times).oute of administration.
Belief: speed of actionaz Adjusted estimated prevalence












e mean of total sample (ACQ-6 score ¼ 2.62, sd ¼ 0.52; frequency of resorting to
) ¼ 0.64, sd ¼ 1.46). **Asthma-related treatment regimen held constant at their
Table 3




N ¼ 28 (18.7%)
Preference for SC
N ¼ 122 (81.3%)
p
Age 48.8 (12.1) 52.7 (9.19) 47.9 (12.5) 0.038
ACQ-6 2.62 (0.52) 2.73 (0.71) 2.60 (0.47) > 0.10
Complexity of treatment regimen 2.12 (0.71) 2.07 (0.77) 2.13 (0.70) > 0.10
Last exacerbation remedies
Corticosteroid dose escalation 1.76 (1.29) 1.25 (1.40) 1.88 (1.24) 0.028
Corticosteroid prescription 1.07 (1.02) 0.75 (0.97) 1.14 (1.02) 0.063
Hospitalization 0.55 (0.70) 0.39 (0.63) 0.58 (0.71) > 0.10
Emergency room access 0.96 (0.80) 0.61 (0.68) 1.04 (0.81) 0.009
Body Mass Index 24.1 (2.77) 24.8 (2.66) 23.9 (2.78) > 0.10
Time since asthma diagnosis 25.8 (12.4) 24.9 (12.7) 26.0 (12.4) > 0.10
Medical resource utilization (previous 12 months)
Hospitalization days 1.45 (1.72) 1.25 (1.86) 1.50 (1.69) > 0.10
Outpatients use 4.55 (1.65) 4.46 (1.62) 4.56 (1.67) > 0.10
Emergency room access 1.86 (1.62) 1.86 (1.94) 1.86 (1.54) > 0.10
Mental composite score (SF 12) 54.2 (6.54) 55.1 (7.75) 53.9 (6.23) > 0.10
Physical composite score (SF 12) 37.6 (5.59) 37.7 (6.15) 37.6 (5.48) > 0.10
Sleep quality (0 ¼ very poor - 10 ¼ excellent) 5.61 (1.18) 5.46 (1.48) 5.64 (1.11) > 0.10
Work productivity and activity impairment (WPAI)
Sick leave (asthma related) (%) 4 (0.09) 6 (0.10) 5 (0.09) > 0.10
Presenteeism (%) 28 (0.20) 25 (0.22) 28 (0.20) > 0.10
Total Productivity Loss (%) 33 (0.24) 31 (0.27) 33 (0.24) > 0.10
N (%) N (%) N (%)
Women 79 (52.7) 14 (50.0) 65 (53.3) > 0.10
Geographic area
North 32 (21.3) 4 (14.3) 28 (22.9) > 0.10
Centre 47 (31.3) 12 (42.9) 35 (28.7)
South 30 (20.0) 3 (10.7) 27 (22.1)
Islands 41 (27.3) 9 (32.1) 32 (26.2)
Route of administration of current asthma-related medication
Spray 136 (90.7) 28 (100) 108 (88.5) 0.06
Subcutaneous 49 (32.7) 0 49 (40.2) < .000
Oral 97 (64.7) 18 (64.3) 79 (64.7) > 0.10
Current asthma-related medication
Corticosteroid 76 (50.7) 7 (25.0) 69 (56.6) 0.003
Biologica 48 (32.0) 0 48 (39.3)
Allergy 132 (88.0) 23 (82.1) 109 (89.3)
Previous/current experience of SC formulation of biologic
therapy for asthma
54 (36.0) 5 (17.9) 49 (40.2) 0.03
Employed 116 (77.3) 20 (71.4) 96 (78.7) > 0.10
Exposure to occupational risk (metal fumes/flour/stinging
powder or gas)
82 (54.7) 19 (67.9) 63 (51.6) > 0.10
Values are shown as mean (standard deviation, sd). P values represent confidence levels of t-test for continuous variables, χ2 for categorical variables.
a SC formulation (i.e. SC mepolizumab or omalizumab) was the only anti IL-5 available route of administration at the time of the investigation.
P. Santus et al. World Allergy Organization Journal 12 (2019) 100030Patients who expressed preference for IV were older (52.7 y vs. 47.9
y; p¼ 0.04); were less likely to escalate corticosteroid dose (1.25 vs. 1.88,
p ¼ 0.03) and to resort to ER access (0.61 vs. 1.04; p ¼ 0.009) during
asthma exacerbation; were less likely to use corticosteroid for current
management of asthma (4.7% vs. 46%; p ¼ 0.003) and to use inhalatory
formulation for current medication (18.7% vs. 72%; p ¼ 0.06).
Patients who reported previous or current experience with SC bio-
logic therapy for asthma expressed greater preference for SC route of
administration compared to IV formulation (32.7% vs. 3.33%; p ¼ 0.03).
Associations between preferences and beliefs towards IV and SC route
of administration are shown in Fig. 1. Overall, patients felt that SC was
more convenient than IV; however, such belief was not associated with
higher likelihood of preferring SC as a route of biologic therapy admin-
istration (2.08 vs. 1.5; p > 0.10).
Furthermore, patients who preferred IV formulations were more
likely to believe that such an administration route would enable quicker
and more effective drug action (p ¼ 0.0001), as well as procedural safety
and medical oversight (p ¼ 0.0002) and social support (p ¼ 0.007)
compared to subjects who expressed preference for SC medication.
Statistically significant predictors of preference for IV route admin-
istration in the multivariable logistic regression model are shown in
Table 4. The interaction between ACQ-6 score and ER use during exac-
erbation was statistically significant (0.76; p ¼ 0.04). Parameter esti-
mates indicated that the strength of association between asthma control4
status and the likelihood of preferring IV formulations increased with
greater use of asthma-related ER services; additionally, beliefs toward
formulation effectiveness/efficiency in reducing symptoms was the only
belief score independently associated with patients’ preferences
(Table 4). The model achieved excellent discrimination of administration
route preference (area under the curve – AUC ¼ 0.87).
In order to simplify the interpretation of regression coefficients we
report ten different hypothetical clinical scenarios illustrating estimated
probabilities of preferring IV route of administration associated to
different values of ACQ-6 score, frequency of resorting to ER services in
case of exacerbations, and beliefs toward differential efficacy across
administration routes. Body mass index and the number of asthma-related
treatments were held constant at the sample average (Table 2). The
reference patient in our sample (case G) had 19% probability of preferring
IV administration. The probability of preferring IV administration rose as
the patients had more intractable disease (i.e. higher ACQ-6 score), was
more likely to access ER in case of exacerbation andmore strongly believed
IV was more effective than SC administration.
Discussion
This study investigated preference and beliefs towards IV and SC
routes of administration of biologic therapy among patients suffering
from inadequately controlled severe asthma.
Fig. 1. Association between preferences and beliefs towards IV and SC routes of administration for total, SC and IV sample. SC ¼ subcutaneous; IV ¼ intravenous.
P. Santus et al. World Allergy Organization Journal 12 (2019) 100030Our findings revealed SC formulation was the preferred route of
administration, chosen as a hypothetical add-on therapy by more than
80% of participants.
Patients’ beliefs toward procedural safety and medical oversight,
social support, efficacy and speed of action were associated with
administration route preference in the univariate analysis. However,
multivariable logistic regression showed that only beliefs toward efficacy
independently affected likelihood estimates. Given the relatively small
sample size and the inter-correlation between beliefs dimensions, it may
not be possible to disentangle the independent effect of each belief within
this study. Even though multicollinearity was moderate in our analysis,
we cannot exclude that regression estimates were unstable (i.e. sensitive
to small changes) and overly imprecise (i.e. wider confidence intervals
due to multicollinearity).
We also showed that patients with less asthma control were more
likely to opt for IV formulation, especially when accesses to ER services in
case of exacerbations were frequent. Taken together, our results suggest
that patients may perceive IV treatment as a more effective drug,
reserved for the most severe or difficult-to-control cases.
Since we observed that patients' beliefs towards route of adminis-
tration may influence their treatment preferences, it is important to
explore in more detail specific beliefs driving patients’ scale scores.
Specifically, our results showed that SC formulation was felt as enabling
more time for daily activities unrelated to disease care (loading ¼ 0.78),
as well as allowing greater convenience compared to IV formulation
(loading ¼ 0.73) and was believed to impose less time spent managingTable 4
Statistically significant predictors of preference for IV route of administration.
Estimates p
ACQ-6 1.04 0.011











Multivariable model adjusted for socio-demographic (age, sex, geographic area,
employment status, high-risk occupation) and clinical characteristics (disease
duration, ACQ-6 score, complexity of treatment regimen, exacerbation remedies,
current and previous medication for asthma, medical resources utilization,
mental and physical SF-12 composite scores, sleep quality, BMI, work produc-
tivity and activity impairment, suffering from allergy, experience with biologic
therapy for asthma).
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asthma (loading ¼ 0.75) and its practical hassles concerned to treatment
administration (loading ¼ 0.70). Conversely, IV route of administration
was associated with less frequent dose administrations (loading ¼ 0.83),
considered faster in reducing symptoms (loading ¼ 0.74) and more
effective (loading¼ 0.52) compared to SC formulation. Such beliefs were
stronger for patients who expressed preference for IV administration, and
it was the most important predictor of IV preference.
Since only a minority (36%) of our sample reported current or pre-
vious treatment with SC biological drugs for asthma, and none had
experience with IV biologics, understanding whether observed beliefs
may rely on false opinions is crucial to informed decision-making.
Indeed, previous studies investigating preference for IV or SC
formulation mostly evaluated patients' perspective after they switched
from one route of administration to another, thus considering directly
experienced trade-offs: compared to IV formulation, SC was frequently
associated with convenience of use since the self-administered procedure
resulted in considerable time savings for patients.11,18 Conversely, both
IV and SC biologic therapy for uncontrolled asthma require a hospital
care setting for administration, which may thus virtually eliminate the
differences across the two formulations in terms of administration time
and organizational burden for the patient; our questionnaire specifically
tapped administration time intrusiveness on daily life and organizational
burden. Unfortunately, we could not debrief patients’ cognitive
answering process to discover how their beliefs were formed. Such un-
derstanding is key to delivering appropriate health education and correct
unfounded beliefs which may affect treatment expectations, decisions
and subsequent treatment satisfaction.
Similar to opinions about convenience, beliefs toward efficacy and
speed of action should be challenged against scientific evidence. Few
studies compared asthma-related drugs with different administration
routes generally showing no statistically significant difference.22 One
notable exception is represented by one randomized controlled trial
(RCT) comparing 4 monthly doses of IV reslizumab against SC mepoli-
zumab (12 monthly doses). The authors observed greater asthma control
among patients on IV reslizumab compared to the comparators in a
subset of severe prednisone-dependent patients with asthma.24 However,
it is not currently possible to discriminate the effect of the active principle
and the impact of the administration route.
Other potentially important beliefs dimensions have been investi-
gated. Previous studies assessing experience with IV biologic therapies
among Inflammatory Bowel Disease and rheumatology patients, showed
satisfaction with IV treatment because it was associated with enhanced
social support and closer procedural oversight from health care pro-
fessionals and physicians.13 In our study, neither social support nor
procedural oversight was felt as a prominent feature of any specific
P. Santus et al. World Allergy Organization Journal 12 (2019) 100030administration and this may be consequently due to lack of experience
with biologic therapy; however, patients preferring IV formulations were
more keen to believe that this route of administration would guarantee a
greater procedural safety and medical oversight.
Given that asthma-related biologics are all administered in hospital
settings, and RCTs have proven both mepolizumab, reslizumab and
benralizumab to be safe,13 reasons driving patients’ beliefs should be
investigated further.
Finally, this study has some limitations. First, it is a cross-sectional
survey, and our patients have been invited to speculate on a hypotheti-
cal scenario since, at the time of the survey, no IV formulation was
marketed worldwide. As a consequence, we cannot directly infer actual
behavior should the patients face a real option. Moreover, we acknowl-
edge that the inclusion of patients with a previous or current experience
of biologic treatment may represent a confounder; in this view, the
multivariate model was adjusted for treatment regimens and previous
biologics use. Indeed, we believe that the study sample could reflect a
real life clinical scenario in outpatient clinics that are responsible for the
everyday management of patients with asthma. Second, the beliefs to-
ward administration modality scale (BAM) was developed for the study
since no existing questionnaire tapped the dimensions of interest. Even
though the basic psychometric properties corroborated the suitability of
BAM among patients with uncontrolled asthma, further studies should
replicate our results. Finally, recruitment was based on a patients’ self-
administered screener questionnaire. As a result, we cannot exclude se-
lection bias limiting the generalizability of the study.
Conclusions
This study investigated preferences and beliefs towards IV and SC
route of administration among patients with severe uncontrolled asthma
reporting limited experience with biologic therapies. We found prefer-
ence to be guided by partially misleading beliefs, which may generate
wrong expectations that in turn may affect treatment satisfaction and
adherence; clinicians should be aware of possible cognitive bias in order
to provide patients with correct information and health education.
Overall, our findings suggest that beliefs toward convenience and effi-
cacy of drugs with different routes of administrations should be formally
elicited and discussed during doctor-patient interaction to achieve
informed shared-decision making.
Patients with severe asthma are at risk of increased morbidity and
have a substantial impact in terms of healthcare utilizations; thus iden-
tifying optimal treatment regimen is fundamental.20 In light of similar
efficacy and safety profiles of identified medications, patients’ preference
assumes a relevant role thus making a shared decision with clinicians on
realistic information essential. Further studies are needed to deeply
investigate preference among patients with uncontrolled severe asthma,
and to determine their role over compliance, satisfaction and perception
of treatment efficacy.
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